AXP Q1 2026 Earnings EPS Beat Drives Cautious Optimism NCMI Q1 2026 Earnings EPS Misses Estimates Amid Challenging Advertising Environment GLDG Q1 2026 Earnings Narrowerthanexpected loss as exploration ramp continues NervGen Pharma Q3 2025 Earnings Narrowed Loss Meets Estimates But Stock Plunges 43 Origin Materials Q4 2025 Earnings Massive EPS Miss and Zero Revenue Highlight Ongoing Challenges LOW Q1 2026 Earnings EPS Beats Estimates by 092 Stock Dips Slightly